Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC

MONDAY, Sept. 12, 2022 -- Fifty-one percent of patients receiving neoadjuvant therapy with cemiplimab for resectable stage II, III, or IV (M0) cutaneous squamous cell carcinoma had a pathological complete response, according to a study published...